Cassava Sciences Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while iShares 0 3 Month Treasury Bond ETF trades at $100.55. The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SGOV | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $100.74 |
52-Week Low | $1.09 | $100.28 |
Enterprise Value | -$33.43M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.545, up 0.02% over 24 hours, with technical indicators showing a bullish trend from moving averages but mixed signals from oscillators. The ETF offers a low-risk cash alternative with a yield around 3.5–3.65% and minimal expense ratio of 0.09%, attracting significant investor inflows amid rate uncertainty. Recent news highlights its role in diversification and income strategies for conservative portfolios.
Outlook remains positive for SGOV as a safe-haven asset, benefiting from Federal Reserve policy speculation and demand for short-term yield. Risks include interest rate volatility and competition from similar ETFs. Wall Street sentiment is favorable, with analysts endorsing its cost efficiency and liquidity for cash management.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →